Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:319589D84.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency is a rare inherited immune disorder that makes a person unusually vulnerable to infections caused by mycobacteria. Mycobacteria are a group of germs that include the bacteria causing tuberculosis (TB) and a large family of environmental organisms called nontuberculous mycobacteria (NTM), which are normally harmless to most people. In this condition, the body's immune defense system does not respond properly to a key signaling molecule called interferon-gamma (IFN-gamma). Specifically, part of the receptor that detects IFN-gamma — called the IFN-gamma receptor 2 (IFNgammaR2) — does not work correctly, but it still has some remaining function (partial deficiency). Because the receptor is only partially impaired, the immune system can still mount some defense, which generally leads to a milder disease course compared to complete deficiency. Patients typically develop recurrent or severe infections with mycobacteria, including BCG disease after vaccination, disseminated nontuberculous mycobacterial infections, and sometimes tuberculosis. Other organisms such as Salmonella, certain fungi, and intracellular parasites may also cause unusual infections. Symptoms often include prolonged fevers, swollen lymph nodes, bone infections, lung infections, and skin lesions. The condition is usually diagnosed in childhood, though the age of onset can vary. Treatment focuses on aggressive and prolonged antibiotic therapy targeting the specific mycobacterial infection, and in some cases, supplemental interferon-gamma therapy may be used to boost the immune response. With appropriate management, many patients with partial deficiency have a better outlook than those with complete deficiency.

Also known as:

Key symptoms:

Recurrent or severe infections with mycobacteriaProlonged or unexplained feversSwollen lymph nodes that do not go awayLung infections or persistent coughBone infections (osteomyelitis)Skin nodules or abscessesSevere reaction to BCG vaccineWeight loss or failure to thrive in childrenFatigue and general weaknessInfections with Salmonella bacteriaLiver or spleen enlargementRecurrent infections that are hard to treat

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency.

View clinical trials →

No actively recruiting trials found for Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency community →

No specialists are currently listed for Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiencyForum →

No community posts yet. Be the first to share your experience with Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency.

Start the conversation →

Latest news about Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency

No recent news articles for Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my (or my child's) IFNgammaR2 deficiency, and how much receptor function remains?,What infections should I watch for, and what are the early warning signs?,How long will antibiotic treatment need to continue?,Is interferon-gamma therapy recommended in our case, and is it available?,Should family members be genetically tested for this condition?,Are there any vaccines that should be avoided?,What precautions should we take in daily life to reduce infection risk?

Common questions about Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency

What is Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency?

Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency is a rare inherited immune disorder that makes a person unusually vulnerable to infections caused by mycobacteria. Mycobacteria are a group of germs that include the bacteria causing tuberculosis (TB) and a large family of environmental organisms called nontuberculous mycobacteria (NTM), which are normally harmless to most people. In this condition, the body's immune defense system does not respond properly to a key signaling molecule called interferon-gamma (IFN-gamma). Specifically, par

How is Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency inherited?

Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency typically begin?

Typical onset of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency is childhood. Age of onset can vary across affected individuals.